Veru initiated with an Outperform at Raymond James

Raymond James analyst Gary Nachman initiated coverage of Veru with an Outperform rating and $3 price target. Veru has pivoted with its key product, enobosarm, to rapidly pursue muscle loss associated with GLP-1 weight loss drugs and enobosarm’s large database “provides strong validation” for its mechanism of action as a SARM increasing muscle with good safety, the analyst tells investors.